BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,057 | -95.4% | 90,242 | -52.5% | 0.00% | -96.8% |
| Q2 2023 | $391,266 | -37.6% | 189,935 | 0.0% | 0.06% | -56.3% |
| Q1 2023 | $626,786 | +101.2% | 189,935 | 0.0% | 0.14% | +89.3% |
| Q4 2022 | $311,494 | -62.9% | 189,935 | 0.0% | 0.08% | -55.1% |
| Q3 2022 | $839,000 | +20.2% | 189,935 | -25.1% | 0.17% | +31.5% |
| Q2 2022 | $698,000 | -31.7% | 253,432 | -16.7% | 0.13% | -5.2% |
| Q1 2022 | $1,022,000 | -11.8% | 304,161 | +5.0% | 0.13% | -22.5% |
| Q4 2021 | $1,159,000 | +21.4% | 289,550 | 0.0% | 0.17% | +158.2% |
| Q3 2021 | $955,000 | -14.3% | 289,550 | -1.2% | 0.07% | -25.6% |
| Q2 2021 | $1,115,000 | -0.6% | 293,200 | 0.0% | 0.09% | +136.8% |
| Q1 2021 | $1,122,000 | -94.3% | 293,200 | -74.9% | 0.04% | -97.3% |
| Q3 2020 | $19,797,000 | – | 1,170,100 | – | 1.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABNER HERRMAN & BROCK LLC | 241,500 | $1,093,000 | 0.17% |
| OCCUDO QUANTITATIVE STRATEGIES LP | 90,584 | $410,000 | 0.13% |
| EPIQ PARTNERS, LLC | 10,550 | $48,000 | 0.03% |
| Phoenix Holdings Ltd. | 173,683 | $799,000 | 0.02% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 5,500 | $25,000 | 0.02% |
| CFO4Life Group, LLC | 12,003 | $54,000 | 0.02% |
| HighPoint Advisor Group LLC | 15,733 | $115,000 | 0.01% |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 357,761 | $1,619,000 | 0.01% |
| Virtu Financial LLC | 24,484 | $111,000 | 0.01% |
| ETF MANAGERS GROUP, LLC | 93,902 | $435,000 | 0.01% |